Getting a drug approved is slow, and a lot of the wait is the data. A trial runs for years, then the results are packaged up and sent to the regulator, who reads through the lot. On 27 May, the US Food and Drug Administration said it wants to change that, starting with two pilot trials that feed their results to the agency as they happen.

What "real-time" actually means here

Instead of a single submission at the finish line, the two proof-of-concept trials will report their endpoints and data signals to the FDA continuously. AI and cloud tools do the heavy lifting, flagging patterns and cleaning data as it arrives rather than months later. The agency took public comments on the plan until 29 May, so the framework is still being shaped.

How much time it could save

The FDA's chief AI officer, Jeremy Walsh, said the approach could cut 20 to 40 per cent off the overall length of a trial. That is the agency's own estimate, and the pilots will test whether it holds. Even the low end would be meaningful. For a patient waiting on a treatment for a serious illness, months are not an abstraction.

The catch worth keeping in mind

Faster is good until it is rushed. Watching trial data in real time, with software helping interpret it, raises a fair question about whether speed quietly erodes the caution that makes approvals trustworthy. The FDA is framing this as efficiency, not a lower bar, and the same day it cleared a new cancer therapy through its normal process. The pilots are small for a reason. The thing to watch is whether the standard of evidence stays put as the clock speeds up.

Why it reaches beyond the US

The FDA sets the tempo that other regulators, including those across Asia, tend to follow. If real-time reporting works, expect the model to travel. For anyone who has watched a family member wait out a slow approval, a shorter path is the kind of behind-the-scenes change that eventually shows up in a clinic.